Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop
Fierce Pharma
OCTOBER 3, 2023
After a confirmatory trial flop this past summer, Takeda is calling it quits on its targeted non-small cell lung cancer (NSCLC) drug Exkivity. Takeda will work with the FDA to chart a voluntary withdrawal of Exkivity in the U.S.,
247 
Let's personalize your content